Phase I Clinical Trial Data Review Complete - RECCE® 327 as an Intravenous Infusion Formulation
Highlights:
Independent examiners confirm Phase I R327 (I.V.) study in 80 human subjects
(eight cohorts), achieved all primary study end-points, met international regulatory
standards in data and showed R327 to be safe & well tolerated
Dosing was achieved commensurate with efficacy demonstrated in Gram-positive
& Gram-negative animal infection models to date
Phase I/II ‘fast infusion’ dosing of R327 IV is tracking to primary study end-points
with expected data read-outs in H2 2023
Phase I Clinical Trial Data Review Complete - RECCE® 327 as an...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
44.5¢ |
Change
0.080(21.9%) |
Mkt cap ! $128.6M | |||
| Open | High | Low | Value | Volume |
| 37.5¢ | 44.5¢ | 37.5¢ | $191.2K | 477.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 12222 | 44.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.0¢ | 10976 | 2 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| RCE (ASX) Chart |